Targeting low molecular weight cyclin E (LMW-E) in breast cancer

Breast Cancer Research and Treatment

Volumn 132, Issue 2, 2012, Pages 575-588

  Nanos Webb, Angela ^a   Jabbour, Natalie A ^a   Multani, Asha S ^a   Wingate, Hannah ^a   Oumata, Nassima ^b   Galons, Hervé ^c   Joseph, Benoît ^d   Meijer, Laurent ^e   Hunt, Kelly K ^a   Keyomarsi, Khandan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Centre de Perharidy   (France)

^c CNRS   (France)

^d UNIVERSITÉ LYON 1   (France)

^e STATION BIOLOGIQUE   (France)

Author keywords

CDK inhibitors; CYC202; Doxorubicin; LMW cyclin E; Roscovitine; Seliciclib

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; DOXORUBICIN; MERIOLIN DERIVATIVE; PURINE DERIVATIVE; PYRAZINE DERIVATIVE; ROSCOVITINE; UNCLASSIFIED DRUG; VARIOLIN B;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHROMOSOME ABERRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ABERRATIONS; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; ENZYME INDUCTION; FEMALE; GENOMIC INSTABILITY; HUMANS; MOLECULAR WEIGHT; POLYPLOIDY; PROTEIN KINASE INHIBITORS; PURINES; TIME FACTORS; TRANSFECTION;

EID: 84859104315     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1638-4     Document Type: Article

References (36)

1. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821-18282
2. Myung K, Datta A, Kolodner RD (2001) Suppression of spontaneous chromosomal rearrangements by S phase checkpoint functions in Saccharomyces cerevisiae. Cell 104:397-408 (Pubitemid 32206460)
3. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M (1995) Human cyclin E, anuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15:2612-2624
4. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M, Roberts JM (1991) Human cyclin E, anew cyclin that interacts with two members of the CDC2 gene family. Cell 66:1217-12285
5. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR, Roberts JM (1992) Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257:1689-1694
6. Keyomarsi K, Pardee AB (1993) Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90:1112-1116 (Pubitemid 23053961)
7. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB (1994) Cyclin E, apotential prognostic marker for breast cancer. Cancer Res 54:380-3858
8. Resnitzky D, Gossen M, Bujard H, Reed SI (1994) Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14:1669-1679
9. Sauer K, Lehner CF (1995) The role of cyclin E in the regulation of entry into S phase. Prog Cell Cycle Res 1:125-13910
10. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS (2002) Cyclin Eand survival in patients with breast cancer. N Engl J Med 347:1566-1575 (Pubitemid 35315837)
11. Harwell RM, Porter DC, Danes C, Keyomarsi K (2000) Processing of cyclin Ediffers between normal and tumor breast cells. Cancer Res 60:481-489 (Pubitemid 30070779)
12. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K (2001) Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecularweight forms. Mol Cell Biol 21:6254-6269 (Pubitemid 34263525)
13. Porter DC, Keyomarsi K (2000) Novel splice variants of cyclin E with altered substrate specificity. Nucleic Acids Res 28:E101
14. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64:3198-320815
15. Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, Tucker SL, Van Pelt C, Meijer L, Hunt K, Keyomarsi K (2009) Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle 8:1062-1068
16. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67:7212-7222 (Pubitemid 47206549)
17. Cyclacel (2007) Investigator's Brochure Seliciclib (CYC202, R-Roscovitine) 1-88
18. Smith P, Yue E (2006) CDK inhibitors of cyclin-dependent kinases as anti-tumor agents. Monographs on enzyme inhibitors. CRC Press Taylor, Francis, Boca Raton, FL
19. Shapiro GI (2006) Cyclin-dependent kinase pathways astargets for cancer treatment. J Clin Oncol 24:1770-178320
20. Malumbres M, Pevarello P, Barbacid M, Bischoff JR (2008) CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 29:16-21
21. Galons H, Oumata N, Meijer L (2010) Cyclin-dependent kinase inhibitors: asurvey of recent patent literature. Expert Opin Ther Pat 20:377-404
22. Keyomarsi K, Conte D Jr, Toyofuku W, Fox MP (1995) Deregulation of cyclin Ein breast cancer. Oncogene 11:941-950
23. Pathak S (1976) Chromosome banding techniques. J Reprod Med 17:25-28
24. Delk NA, Hunt KK, Keyomarsi K (2009) Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclindependent kinase 2 complex formation and proteasomal regulation. Cancer Res 69:2817-2825
25. Meijer L, Raymond E (2003) Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 36:417-425
26. Aldoss IT, Tashi T, Ganti AK (2009) Seliciclib in malignancies. Expert Opin Investig Drugs 18:1957-196527
27. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C (2007) A phase Itrial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96:29-37 (Pubitemid 46094635)
28. Hsieh WS, Soo R, Peh BK, Loh T, Dong D, Soh D, Wong LS, Green S, Chiao J, Cui CY, Lai YF, Lee SC, Mow B, Soong R, Salto-Tellez M, Goh BC (2009) Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res 15:1435-1442
29. Bettayeb K, Tirado OM, Marionneau-Lambot S, Ferandin Y, Lozach O, Morris JC, Mateo-Lozano S, Drueckes P, Schachtele C, Kubbutat MH, Liger F, Marquet B, Joseph B, Echalier A, Endicott JA, Notario V, Meijer L (2007) Meriolins, anew class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res 67:8325-8334 (Pubitemid 47395171)
30. Echalier A, Bettayeb K, Ferandin Y, Lozach O, Clement M, Valette A, Liger F, Marquet B, Morris JC, Endicott JA, Joseph B, Meijer L (2008) Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. J Med Chem 51:737-751 (Pubitemid 351304683)
31. Mettey Y, Gompel M, Thomas V, Garnier M, Leost M, Ceballos-Picot I, Noble M, Endicott J, Vierfond JM, Meijer L (2003) Aloisines, anew family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem 46:222-236 (Pubitemid 36078142)
32. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K (2010) Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 70:5074-5084
33. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair KW, Kaelin WG Jr (1999) Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 96:4325-4329 (Pubitemid 29190335)
34. Ganem NJ, Godinho SA, Pellman D (2009) A mechanism linking extra centrosomes to chromosomal instability. Nature 460:278-282
35. Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, Compton DA, Dmitrovsky E (2010) Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res 16:109-120
36. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K (2008) Autophagy: anovel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68:7966-7974